These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6259352)

  • 1. Synthesis and angiotensin-converting enzyme inhibitory activity of 3-(Mercaptomethyl)-2-oxo-1-pyrrolidineacetic acids and 3-(Mercaptomethyl)-2-oxo-1-piperidineacetic acids.
    Klutchko S; Hoefle ML; Smith RD; Essenburg AD; Parker RB; Nemeth VL; Ryan MJ; Dugan DH; Kaplan HR
    J Med Chem; 1981 Jan; 24(1):104-9. PubMed ID: 6259352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and pharmacological screening of new angiotensin converting enzyme inhibitors.
    Gubert S; Braso MA; Sacristán A; Ortiz JA
    Farmaco; 1990 Jan; 45(1):59-79. PubMed ID: 2186741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
    Seymour AA; Asaad MM; Lanoce VM; Langenbacher KM; Fennell SA; Rogers WL
    J Pharmacol Exp Ther; 1993 Aug; 266(2):872-83. PubMed ID: 8394922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Synthesis and pharmacological activity of some carboxy pyrrolidinones and several derivatives (author's transl)].
    Robert J; Boucherle A
    Ann Pharm Fr; 1981; 39(4):337-46. PubMed ID: 7305244
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme.
    Almquist RG; Chao WR; Ellis ME; Johnson HL
    J Med Chem; 1980 Dec; 23(12):1392-8. PubMed ID: 6256550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.
    Kaplan HR; Cohen DM; Essenburg AD; Major TC; Mertz TE; Ryan MJ
    Fed Proc; 1984 Apr; 43(5):1326-9. PubMed ID: 6323223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and angiotensin converting enzyme inhibitory activity of N-carboxymethyldipeptides with omega-(4-piperidyl)alkyl group.
    Waga T; Matsui S; Saito S; Watanabe M; Kajiwara Y; Shirota M; Iijima M; Kitabatake K
    Arzneimittelforschung; 1990 Apr; 40(4):407-13. PubMed ID: 2162675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues.
    Anwar M; Bailey JH; Dickinson LC; Edwards HJ; Goswami R; Moloney MG
    Org Biomol Chem; 2003 Jul; 1(13):2364-76. PubMed ID: 12945710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal by acetylsalicylic acid of the captopril-induced inhibition of angiotensin converting enzyme in the hindquarters of guinea-pig.
    Melli M; Türker RK
    Arch Int Pharmacodyn Ther; 1982 May; 257(1):87-93. PubMed ID: 6287951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemico-pharmaceutical and pharmacodynamic characteristics of pyrglutargine].
    Selleri R; Orzalesi G; Innocenti F; Volpato I; Bisagno T
    Boll Chim Farm; 1977 Dec; 116(12):735-43. PubMed ID: 610732
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
    Stanton JL; Watthey JW; Desai MN; Finn BM; Babiarz JE; Tomaselli HC
    J Med Chem; 1985 Nov; 28(11):1603-6. PubMed ID: 2999394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelium-dependent relaxation by angiotensin-converting enzyme inhibitors in canine femoral arteries.
    Moroi M; Akatsuka N; Fukazawa M; Hara K; Ishikawa M; Aikawa J; Namiki A; Yamaguchi T
    Am J Physiol; 1994 Feb; 266(2 Pt 2):H583-9. PubMed ID: 8141360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
    J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin converting enzyme inhibitors potentiate the bronchoconstriction induced by substance P in the guinea-pig.
    Subissi A; Guelfi M; Criscuoli M
    Br J Pharmacol; 1990 Jul; 100(3):502-6. PubMed ID: 1697196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The actions of enkephalins are not modified by the "kininase-II" inhibitor captopril.
    Buckett WR
    Eur J Pharmacol; 1979 Aug; 57(2-3):267-71. PubMed ID: 226377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
    Westlin W; Mullane K
    Circulation; 1988 Jun; 77(6 Pt 2):I30-9. PubMed ID: 2836109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivatives of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline: effect of changes at positions 2 and 5 of the hexanoic acid portion.
    Almquist RG; Crase J; Jennings-White C; Meyer RF; Hoefle ML; Smith RD; Essenburg AD; Kaplan HR
    J Med Chem; 1982 Nov; 25(11):1292-9. PubMed ID: 6292422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro.
    Balcells E; Meng QC; Hageman GR; Palmer RW; Durand JN; Dell'Italia LJ
    Am J Physiol; 1996 Aug; 271(2 Pt 2):H417-21. PubMed ID: 8770078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.